Bionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) recently participated in the European Cytogenomics Conference, which is the biennial meeting of the European Cytogenomics Association (ECA). The conference was held in Leuven, Belgium, from June 29 – July 1 and attracted leading scientists, clinicians, cytogeneticists and laboratory directors from across Europe and the Middle East.

Key Highlights from ECA 2025:

Optical Genome Mapping workshops: The ECA organizers hosted two hands-on workshops on June 29 focused on applications of VIA™, Bionano’s comprehensive analytical suite for structural variation analysis from next-generation sequencing (NGS), microarray and OGM data. These sessions were co-led by Bionano representatives and three key opinion leaders (KOLs) in the field:

Amber Verhasselt – UZ Leuven, Belgium
Barbara Dewaele – UZ Leuven, Belgium
Jean-Michel Dupont – Cochin Hospital, AP-HP, France

Scientific Presentations and Posters: The number of presentations of OGM scientific content at the ECA conference has grown over recent years. In 2025, a total of 16 studies—including oral presentations and posters—were presented by authors from seven countries. This represents an increase compared to 2023, which featured 14 studies, and to 2021, which featured nine. Specific presentations and their authors and affiliations are noted in the table below. The scientific program for the event is available at the ECA website linked here https://www.eca2025.org/en/SCIENTIFIC-PROGRAMME.html.

Talk/Poster Title	Author	Institution
New insights affecting classification, prognosis and treatment of Multiple Myeloma using Optical Genome Mapping	Hila Lederman Nachmias	Genetics Institute, Tel Aviv Sourasky Medical Center, Israel
InvDupFel Or DupTrp Rearrangements revisited using Array-CGH and Optical Genome Mapping	Martine Doco-Fenzy	CHU Nantes, France
Optical Genome Mapping reveals Germline and Somatic findings that may Influence the Treatment approach	Nivin Moustafa-Hawash	Rambam Health Care Campus, Haifa, Israel
Optical Genome Mapping is A Powerful Diagnostic Tool In Non-Hodgkin Lymphoma	Amber Verhasselt	Centre for Human Genetics, University Hospitals, Leuven, Belgium
Precision approaches in the role of Optical Genome Mapping and Long Read Sequencing in structural variant detection	Dominik Rezny	Fakultní nemocnice Brno, Czech Republic
Improved detection of cytogenetic abnormalities in Multiple Myeloma (MM) using Optical Genome Mapping (OGM)	Nicolas Catarin, Catherine Menten	CHU Liège, Belgium
Optimization of the routine workflow for Myeloid/Lymphoid Neoplasms with eosinophilia and Tyrosine Kinase gene fusions (MLN-TK) by Optical Genome Mapping	Justine Vanhevel, Barbara Dewaele	Centre for Human Genetics, University Hospitals, Leuven, Belgium
Optical Genome Mapping is a powerful tool for detecting significant variants and chromosome abnormalities in hematological diseases	Ariane Mahieux, Nathalie Douet-Guilbert	CHU Brest, France
Optical Genome Mapping improves detection of cryptic aberrations in acute myeloid leukemia	Sarka Ransdorfova, Monika Belickova	Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Intra- and Intertumoral Heterogeneity in Glioblastomas Revealed by Optical Genome Mapping	Lizcova Libuse, Zemanova Zuzana	General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic
Contribution of Optical Genome Mapping to the analysis of structural anomalies of the Y chromosome	Candice Saurin, Kévin Cassinari	Department of Genetics and Reference Center for Developmental Disorders, CHU Rouen, France
Biological Implementation of Optical Genome Mapping in Recurrent Miscarriages and Implantation Failure: A Comprehensive Evaluation	Fatma Maazoun, Jean-Michel Dupont	Department of Genomics Medicine of System and Organs Diseases, Cochin Hospital, AP-HP Center, Paris, France
Characterization of complex chromosomal structural variation: A comparison of cytogenetic methods	Afia Hasnain, Mary Shago	The Hospital for Sick Children, Toronto, Canada
Invdupdel Or Duptrp Rearrangements Revisited by Array-CGH, SNP-Array And Optical Genome Mapping Bionano	Martine Doco-Fenzy, Stéphane Bezieau	CHU Nantes, France
Molecular characterization of human ring chromosomes and complex genomic rearrangements using Optical Genome Mapping and Short-read Genome Sequencing	Rafael Cresti Navarro, Társis Paiva Vieira	Department of Medical Genetics and Genomic Medicine, State University of Campinas, Brazil
Utility of Optical Genome Mapping in Routine Cytogenetic Laboratory Workflow: A Presentation of Two Cases	Tan ML, Lai HMA	KK Women's and Children's Hospital, Singapore

“This European Cytogenomics Conference is a premier event in Europe dedicated to the advancement of cytogenomics. We believe the rising number of contributions at the ECA conference underscores an accelerating use of OGM in the clinical cytogenomics research community in Europe and the Middle East, and shows that OGM can be a valuable tool for uncovering structural variants that are often missed by traditional cytogenetic methods. We also believe this momentum is just the beginning of a broader shift toward more comprehensive, genome-wide structural variant analysis using OGM. Seeing more institutions embrace OGM to solve complex genetic cases is both validating and inspiring,” commented Dr. Erik Holmlin, Bionano’s president & chief executive officer.

For more information on Bionano’s solutions, visit www.bionano.com.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “can,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies, among other things, and in this release include, but are not limited to, statements regarding OGM’s accelerating use in Europe and the Middle East; OGM’s ability to detect SVs missed by traditional cytogenetic methods; the momentum of a broader shift toward more comprehensive, genome-wide structural variant analysis using OGM; the utility of OGM in applications described in the posters, presentations and workshops given at the ECA conference referenced in this press release; OGM's potential for solving complex genetic cases; the growth and global adoption of OGM; and any other statements not of historical fact. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM use to accelerate in Europe and the Middle East; the failure of OGM to detect SVs missed by traditional cytogenetic methods; the failure of the market to shift toward more comprehensive, genome-wide structural variant analysis using OGM; future publications or presentations that contradict the findings of utility of OGM in applications described in the posters, presentations and workshops given at the ECA conference referenced in this press release; the failure of OGM to solve complex genetic cases; the growth and global adoption of OGM; the failure of OGM adoption to grow and increase in global adoption; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date the statements are made. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this press release.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.